Summary
Efficient and quick reconstitution of T cell compartments in lymphopenic patients is of great importance to prevent opportunistic infections, but remains difficult to achieve. Human T cell proliferation in a TCR-independent manner is possible in vitro with superagonist anti-CD28
antibodies, and such molecules are therefore promising therapeutic tools. Here, we investigated the in vivo effects of superagonist anti-CD28 treatment on human developing and mature T cells, in the recently developed model of "human immune system" BALB/c Rag2 therapy could therefore be of clinical interest in humans, both for beneficial effect on thymic T cell production as well as regulatory T cell accumulation.
Introduction
T cell lymphopenia is a common side effect in patients undergoing autologous and allogenic hematopoietic stem cell transplantation, increasing the risk of opportunistic infections 1,2 . The reconstitution of the peripheral T cell compartments depends on three major processes: (a) de novo production of naïve T cells in the thymus, with an age-dependant decline due to thymic involution 3 ; (b) slow lymphopenia-driven proliferation of peripheral T cells under the control of environmental TCR cross-reactivity and cytokines, such as IL-7 and IL-15 4, 5 ; and (c)
antigen-driven clonal expansion. However, lymphopenia-driven proliferation and immune responses intrinsically narrow the available T cell repertoire, and this can lead to the outgrowth of clones highly cross-reactive with self-antigens during a phase of lymphopenia,
i.e. when T cell competition for resources like MHC molecules and cytokines is reduced 4, 6, 7 .
Skewing of the T cell repertoire is also observed in mouse bone marrow chimeras reconstituted with limited numbers of immunocompetent T cell precursors 8 . Such a situation can lead to disruption of T cell homeostasis, development of autoimmune diseases and limitation of immune responses to new antigens 9 . Therefore, it appears to be of major importance that intensive de novo T cell production by a functional thymus occurs during such a period of T cell recovery.
Proper activation of naïve T cells relies on surface engagement of both the TCR and costimulatory molecules, and the latter are essential to avoid induction of unresponsiveness of the stimulated T cells 10 . Among the large amount of known costimulatory molecules, CD28
and its ligands of the B7 family have been extensively studied 11, 12 . CD28 triggering is most effective on naïve and resting T cells, and induces the expression of CD40L on their surface.
Its role in the formation of the immunological synapse 13,14 reinforces the idea that CD28
costimulation participates in the decrease of the threshold of T cell activation 15 . Furthermore, in addition to promoting optimal T cell activation, CD28 ligation also prevents T cell anergy
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From and apoptosis 10, [16] [17] [18] . Indeed, polyclonal expansion of T cells can be achieved in vitro by using immobilized monoclonal antibodies to the TCR and CD28 19 . Such an approach has failed in vivo, mainly because the use of anti-TCR complex antibodies leads to the release of pro-apoptotic and pro-inflammatory cytokines 20, 21 . Superagonist (SA) CD28-specific antibodies have the unique properties of inducing T cell activation independent of TCR engagement [22] [23] [24] , and such antibodies may be applied as an alternative for anti-CD3/TCR antibodies. Several promising results of SA anti-CD28 treatment have been described in the rat, specifically on T cell proliferation (both in vitro and in vivo), and regulatory CD4 + CD25 + T cell subset expansion [25] [26] [27] . Overall, these observations suggest that SA anti-CD28 treatment could be used in patients as a tool to improve the recovery from T cell lymphopenia 24 
Statistical analyses.
Data were subjected to two-tail unpaired Student t test analysis where indicated in the figure legends. The obtained p values were considered significant when p<0.05. 
Accumulation and accelerated differentiation of human thymocytes after treatment
By using the HIS (BALB-Rag/γ) mouse model, we assessed the effect of SA anti-CD28 mAb therapy on human T cells in vivo. The animals were given a single injection with 0.3 mg to 0.03 mg of SA anti-CD28 mAb i.p. and control animals always received the same amount of IgG1 isotype control antibody. Three days after treatment with 0.3 mg of SA anti-CD28 mAb, a substantial increase of thymus cellularity was observed, which was even more pronounced at day 6 with human thymocytes numbers being 7-fold higher in treated animals as compared to control animals ( Fig. 2A) . Using lower doses of mAb strongly reduced the effect on thymus size, with no detectable effect with 0.03 mg (Fig. S1 ). The effect on cell numbers was accompanied by an increase in average cell size of the human thymocytes ( Fig. 2A ) and signs of overt activation and/or differentiation, as assessed by CD25/IL-2Rα, GITR/TNFRSF18 or CD45RO expression (Fig. 2B) . We analyzed the relative distribution of human thymocytes among the different thymic sub-populations, based on expression of CD4/CD8 co-receptors and maturation surface markers. Single positive CD4 + (SP4) and CD8 + (SP8) thymocytes were the major contributors to the global increase in total cell numbers, with an 18-fold and 6-fold increase at day 6, respectively ( Fig. 2A and C) . In comparison, absolute cell numbers of the doublenegative (DN) CD4 -CD8 -and double-positive (DP) CD4 + CD8 + compartments were increased only 2-fold. The treatment was already effective as early as 3 days after injection and reached its optimum at day 6. As a consequence, more than 80% of human thymocytes were SP4 or SP8 at day 6 (Fig. 2C ). In addition, more than 90% of the human thymocytes exhibited a mature CD3 + CD1a -phenotype at day 6 after treatment ( Fig. 2D) , and even DP thymocyte maturation was strongly enhanced (78% of DP cells were CD3 
Effect of treatment on human thymocytes of young HIS (BALB-Rag/γ) mice
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The previous results showed an accumulation of mature thymocytes in the thymus 6 days after SA anti-CD28 treatment of adult HIS (BALB-Rag/γ) mice, which could be due to accelerated differentiation of immature thymocytes to mature SP cells, and/or increased proliferation of already mature T cells after treatment. In order to discriminate between these two possibilities, we evaluated the impact of the treatment on 4 week old reconstituted HIS (BALB-Rag/γ) mice, i.e. when the thymus is mostly composed by immature thymocytes and the peripheral lymphoid organs are not yet significantly populated by human lymphocytes. The effect on the thymus was much less pronounced in SA anti-CD28 treated 4 week old animals, showing limited increase of thymic cellularity as compared with control animals (Fig. 3A) . The human thymocytes were not skewed to mature single positive T cells, although more activated CD25 + single positive T cells could be observed in some animals (not shown).
Furthermore, subset distribution based on the CD4/CD8 coreceptors or CD3/CD1a surface markers was similar between groups ( Fig. 3B/C) , in contrast to what we observed in [8] [9] [10] [11] [12] week old HIS (BALB-Rag/γ) animals ( Fig. 2C/D) . In order to better understand the reason of the treatment ineffectiveness, we examined more carefully the composition of the thymus in HIS (BALB-Rag/γ) mice 4 weeks after reconstitution with human progenitors. As expected, the thymus contained at this age lower numbers of CD3 + CD27 + cells (Fig. 3D) , i.e. positively selected thymocytes 35 . This observation may explain why the thymocytes of 4 week old HIS (BALB-Rag/γ) mice only expanded moderately after SA anti-CD28 treatment, despite the fact that CD28 was expressed on almost all thymocytes, similarly to adult animals (Fig. 1B) .
Experiments with HIS (BALB-Rag/γ) mice 5 weeks after reconstitution, which contain more 
Increased thymic export of human T cells after SA anti-CD28 treatment .
We next evaluated the impact of the SA anti-CD28 treatment on human peripheral T cells of 8-12 week old HIS (BALB-Rag/γ) mice. While the frequency of T cells was constantly increasing in control animals until it reached 25% of human cells in blood, the percentage of T cells in the treated animals dropped to less than 1% after 2 months (Fig. 4A ).
This drop was already evident 3 days after treatment and affected both CD4 + and CD8 + T cell subsets. Analysis of absolute human T cell numbers showed identical results, and similar 
We consistently observed a partial recovery in peripheral T cells numbers between days 3 (virtually no human T cells in the blood) and day 6 (around 5% T cells within human
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+ cells) (Fig. 4A ), in correlation with the peak of the effect in the thymus (Fig. 2) . This observation suggests that thymic output was increased in treated animals between days 3 and 6. SA anti-CD28 treatment of young HIS (BALB-Rag/γ) mice did not induce any significant accumulation of peripheral T cells at day 6 in any of the performed experiments (not shown), despite the fact that thymus size was increased (Fig. 3) .
Since peripheral T cells were drastically depleted from lymphoid organs only 3 days Since accumulation of "regulatory" CD4 + CD25 + T cells was reported after SA anti-CD28 treatment in rats 27 , the kinetics of this subset were analyzed ( At the peak of the effect (day 6), thymocyte numbers were increased up to 7-fold in SA anti-CD28 treated adult HIS (BALB-Rag/γ) mice, in a dose dependant manner ( Fig. 2A/S1 ). The increased thymus cellularity was accompanied by skewing of the thymocytes to a more mature phenotype (SP4/8, CD1a -CD3 + ) ( Fig. 2C/D) . These effects were due to increased proliferation of mature thymocytes, and our results argue against accelerated differentiation of DP thymocytes after treatment. The effect of the treatment was much less on human thymocytes at 4 weeks of age, when production of fully mature T cells is not yet achieved, only inducing a limited increase of cellularity without phenotypic skewing (Fig. 3 ) Therefore, positively selected mature SP thymocytes are the major target of SA anti-CD28 mAb in the thymus and SA anti-CD28 treatment does not bypass T cell positive selection. As far as thymopoiesis recovery after BM transplantation is concerned, it can therefore be speculated that the use of SA anti-CD28 would potentially be of interest when mature T cells have already accumulated in the thymus.
Since thymocyte accumulation is observed to some extent, SA anti-CD28 treatment in 4 week old HIS (BALB-Rag/γ) mice is not inert, although not fully efficient. One explanation for these results is that only 6-8 week old but not 4 week old mice contain many more mature SP week old HIS (BALB-Rag/γ) animals may therefore reflect activation of CD28-specific TCRindependent pathways in immature thymocytes.
In contrast to what was previously reported in rats 25, 26 , the treatment induced a rapid and specific depletion of human peripheral T cells. Mature T lymphocytes were almost undetectable at day 3 after treatment (Fig. 4) . Between day 3 and day 6, a partial recovery in human peripheral T cell numbers was observed in SA anti-CD28 treated HIS (BALB-Rag/γ) mice, correlating with the effect seen in the thymus. This observation argues for a transient increase of thymic output, due to the effect of the treatment on thymocytes, which in turn 26 . In this experimental setting, the rate of de novo CD45 a+ T cell production was evaluated in the blood and was found unmodified after SA anti-CD28 treatment, or moderately increased at 2 weeks, but detailed analysis of the rat thymuses was not performed 26 . In a situation of optimal thymic output and/or recovery, e.g. in the previously mentioned reconstituted rats, SA anti-CD28 treatment may not be able to further increase thymic production. On the opposite, a beneficial effect may be revealed in suboptimal conditions, e.g. in HIS (BALB-Rag/γ) mice which show to some extent characteristics of chronic T cell lymphopenia and limited thymic output.
Despite a T cell increase in SA anti-CD28 treated animals between days 3 and 6, the T cell pool did not recover completely, when monitored over a 2 months period (Fig. 4) . Alternatively, T cell depletion in the periphery could be due to a defective T cell survival in T cell lymphopenia is associated with several human autoimmune diseases, including insulindependent diabetes mellitus, rheumatoid arthritis and lupus 9 . Similar observations have been obtained in rodent models, and it was recently shown in the diabetes-prone NOD mouse model that chronic lymphopenia leads to activation of effector T cells undergoing homeostatic proliferation, which will eventually results in tissue damage 49, 50 . Using SA anti-CD28 mAb in rats was efficient enough to block the induction of experimental autoimmune neuritis 51 For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
